Clinical Evaluation of Atenolol in Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 513s-515s
Author(s):  
L. Hansson ◽  
B. E. Karlberg ◽  
H. Åberg ◽  
A. Westerlund ◽  
N. C. Henningsen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Blocking Agent ◽  
Long Term Results ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Arterial Blood ◽  
Obstructive Airways Disease ◽  
Blind Comparison

1. Atenolol (ICI 66.082, Tenormin) is a new β-adrenoreceptor-blocking agent, devoid of intrinsic sympathomimetic and membrane-stabilizing properties. It does not cross the blood—brain barrier. 2. Atenolol given to hypertensive patients in initial open trials reduced arterial blood pressure significantly. 3. A double-blind comparison between atenolol and placebo in forty-five patients with essential hypertension demonstrated that atenolol gave a statistically significant reduction of blood pressure (Δ 28/15 mmHg, P < 0·005). 4. The optimum anti-hypertensive dose of atenolol in patients with mild to moderately severe essential hypertension was 200 mg daily. 5. Atenolol was compared with propranolol in thirty patients with essential hypertension. No statistically significant differences of anti-hypertensive effect were observed between the two drugs. 6. Long-term results (up to 2 years) in 117 hypertensive patients indicate that drug tolerance is good. No serious toxic effects were observed. 7. In four of twelve hypertensive patients with obstructive airways disease atenolol had to be withdrawn owing to deterioration of ventilatory function.

Double-Blind Comparison of Minoxidil and Hydrallazine in Severe Hypertension

1976 ◽  
Vol 51 (s3) ◽  
pp. 593s-595s ◽  
Author(s):  
G. Connor ◽  
R. L. Wilburn ◽  
C. M. Bennett
Keyword(s):  
Blood Pressure ◽  
Severe Hypertension ◽  
Good Control ◽  
Pressure Control ◽  
Patient Acceptance ◽  
Pressure Side ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Blind Comparison

1. Thirty moderately severely hypertensive patients were studied in a double-blind comparison of minoxidil and hydrallazine in combination with frusemide and propranolol. 2. Blood pressure control in both groups of patients was satisfactory but long-term control appeared to be better in the minoxidil group. 3. Renal function was well preserved in both groups. Evidence of cardiac hypertrophy was slow to resolve despite good control of blood pressure. Side effects were negligible, and patient acceptance and rehabilitation was excellent.

scholarly journals Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study

2019 ◽  
Vol 20 (3) ◽  
pp. 147032031986889 ◽  
Author(s):  
Piotr Ruszkowski ◽  
Anna Masajtis-Zagajewska ◽  
Michał Nowicki
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Angiotensin Converting Enzyme ◽  
Endothelial Function ◽  
Enzyme Inhibitor ◽  
Converting Enzyme ◽  
C Reactive Protein ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Reactive Protein

Background: The aim of this study was to compare the influence of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on endothelial function and blood pressure in patients with essential hypertension on long-term angiotensin-converting enzyme inhibitor therapy. Method: The study was designed as a prospective, double-blind, randomised, placebo controlled, crossover clinical trial. Twenty patients with essential hypertension were treated with an angiotensin-converting enzyme inhibitor; the control group included 10 healthy subjects. Hypertensive patients received in random order 80 mg of fluvastatin daily or placebo for 6 weeks. The following parameters were assessed at baseline and after each treatment period: serum lipids, flow-mediated vasodilation, activity of von Willebrand factor, concentration of vascular endothelial growth factor, C-reactive protein and 24-hour blood pressure profile. Results: Hypertensive patients did not differ from healthy subjects with respect to age, body mass and biochemical parameters, with the exception of C-reactive protein, which was higher in hypertensive patients ( P=0.02). After statin therapy, low-density lipoprotein cholesterol ( P<0.0001), C-reactive protein ( P=0.03), von Willebrand factor ( P=0.03) and vascular endothelial growth factor ( P<0.01) decreased and flow-mediated vasodilation improved ( P<0.001). Statins had no significant effect on blood pressure. Conclusions: Statins added to angiotensin-converting enzyme inhibitors may improve endothelial function and ameliorate inflammation independently of blood pressure.

The Antihypertensive and Renal Activities of Potassium Canrenoate are Associated with Increased Renal Prostaglandin Excretion

1989 ◽  
Vol 77 (2) ◽  
pp. 217-222 ◽  
Author(s):  
Sergio Castellani ◽  
Luca Scarti ◽  
Ji Lin Chen ◽  
Attilio Del Rosso ◽  
Marino Carnovali ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Prostaglandin E2 ◽  
Prostaglandin F2α ◽  
Prostaglandin Synthesis ◽  
Double Blind ◽  
Hypertensive Patients ◽  
Control Subjects ◽  
Potassium Canrenoate ◽  
Normotensive Subjects

1. In a double-blind, randomized, cross-over study the effects of potassium canrenoate administration (100 mg twice daily for 10 days orally) on renal prostaglandin synthesis (prostaglandin E2 and prostaglandin F2α) were evaluated in 10 normotensive females and in 10 females with essential hypertension. 2. When compared with normotensive subjects, hypertensive patients in baseline conditions showed a reduced excretion of urinary prostaglandin E2 associated with an excessive prostaglandin F2α production. 3. Potassium canrenoate significantly reduced mean blood pressure in hypertensive patients [from 118.9 ± 8.7 mmHg (1.62 ± 0.12 kPa) to a peak minimum value of 104.7 ± 9.8 mmHg (1.42 ± 0.13 kPa) on the seventh day of treatment; P < 0.01 for the whole period] but not in control subjects [from 88 ± 9.4 mmHg (1.20 ± 0.13 kPa) to 84.3 ± 8.3 mmHg (1.15 ± 0.11 kPa) on the eighth day, NS] even though potassium canrenoate significantly increased sodium excretion in both groups. Renal prostaglandin excretion was affected differently in the two groups: in control subjects excretion of both prostaglandin E2 and prostaglandin F2α was increased after drug administration, whereas in hypertensive patients only prostaglandin E2 excretion was enhanced.

Haemodynamic Effects of Withdrawal of Long-Term Treatment with β-Adrenoceptor Blocking Agents in Subjects with Essential Hypertension

1981 ◽  
Vol 61 (s7) ◽  
pp. 421s-423s ◽  
Author(s):  
C. Bengtsson ◽  
Y. Larsson ◽  
V. Panfilov ◽  
R. Sivertsson ◽  
H. Åström
Keyword(s):  
Blood Pressure ◽  
Cardiac Output ◽  
Essential Hypertension ◽  
Structural Changes ◽  
Peripheral Resistance ◽  
Blocking Agent ◽  
Term Treatment ◽  
First Year ◽  
Long Term Treatment

1. After 10 years of β-adrenoceptor blockade in five female patients with essential hypertension, the β-adrenoceptor-blocking agent was withdrawn, and the women were then followed up for 1 year, with measurements of cardiac output and peripheral resistance. 2. Blood pressure remained low during the first year after withdrawal in spite of the fact that the heart rate increased within the first few days. 3. Cardiac output was found to increase during the first year after withdrawal, although total peripheral resistance was essentially unchanged. 4. The maintenance of low blood pressure after withdrawal of the antihypertensive drug might indicate a regression of structural changes in the resistance vessels during successful long-term antihypertensive treatment. 5. Minimal resistance in hands and calves did not increase during the year after withdrawal.

Effect of Long-Term, Once-Daily Administration of Atenolol, Metoprolol, Pindolol and Slow-Release Propranolol on Ambulatory Blood Pressure and its Variability

1982 ◽  
Vol 63 (s8) ◽  
pp. 459s-460s ◽  
Author(s):  
J. S. Floras ◽  
J. V. Jones ◽  
M. O. Hassan ◽  
P. Sleight
Keyword(s):  
Blood Pressure ◽  
Slow Release ◽  
Antihypertensive Agents ◽  
Double Blind ◽  
Once Daily ◽  
Arterial Blood ◽  
Before And After ◽  
Receptor Blockers ◽  
Β Receptor

1. Twenty-four-hour intra-arterial blood pressure recordings were made before and after chronic β-receptor blockade in 34 patients with essential hypertension. 2. Subjects were randomized in double blind fashion to either atenolol, metoprolol, pindolol or slow-release propranolol. 3. Drugs were administered in a once-daily variable dose regimen for a period of 3–8 months (mean 5.0 ± sd 1.4). 4. All four drugs reduced blood pressure significantly 24 h after the last dose but there were considerable differences in control when each intervening hour was assessed separately. 5. Not all β-receptor blockers in conventional formulations are equally effective as antihypertensive agents over 24 h when taken once daily.

Sign in / Sign up

Export Citation Format

Share Document